Hosted on MSN9mon
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung CancerOn Friday, Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib ...
The National Institute for Health and Care Excellence (NICE) today announced final draft guidance on Pfizer's Xalkori (crizotinib) and has not recommended it for use in previously-treated ...
Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a phase 3 trial. Takeda has reported updated results from its ALTA-1L trial ...
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results